Jacqueline McBride
Genentech · 109 works · 6,719 citations · h-index 32
Top works
- Cryopyrin activates the inflammasome in response to toxins and ATP
- Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
- Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
- A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)
- Leukocyte functional antigen 1 lowers T cell activation thresholds and signaling through cytohesin-1 and Jun-activating binding protein 1
- Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor
- Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo‐controlled, double‐blind, dose‐escalation study
- IL-10 alters DC function via modulation of cell surface molecules resulting in impaired T-cell responses
- Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE
- DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
- Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma
- Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
- Generation and Protective Ability of Influenza Virus–Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge
- FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
- Two Escape Mechanisms of Influenza A Virus to a Broadly Neutralizing Stalk-Binding Antibody
- Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model
- Adoptive cellular gene therapy of autoimmune disease
- Interleukin 10 regulates cell surface and soluble LIR‐2 (CD85d) expression on dendritic cells resulting in T cell hyporesponsiveness in vitro
- Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients
- The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti‐integrin therapies